Sep 13, 2023 / 12:10PM GMT
Unidentified Analyst -
Good morning. I'm Sam Jones from the Morgan Stanley team. I'm excited to have joining us today, Mike Castagna, CEO of MannKind. Before we get started, I'll read a disclaimer -- so this is research disclosure. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
So Mike, thanks very much for being here today. To start off, it would be great if you could provide an introduction to MannKind, maybe a quick overview of the great progress that you've made over the last few years and where you stand as a company today.
Michael E. Castagna - MannKind Corporation - CEO & Director
Yes, thank you. Thanks for having us today. MannKind has been around 32 years this year. It's been a long time coming. It was originally an inhaled insulin company platform that really was repurposed back in 2017
MannKind Corp at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers